Promising results shown with targeted approaches in subsets of non-small cell lung cancer
Monday, September 29, 2014 - 21:30
in Health & Medicine
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data.